EVOLTRA

The actual benefit of this medicinal product is substantial.

Despite the methodological limitations of this study, the Committee considers that EVOLTRA brings a significant improvement to the actual benefit (IAB II) in the treatment of acute lymphoblastic leukaemia in relapsed or refractory children after at least two lines of treatment. Because in this population, for which there is no therapeutic alternative able to promise a lasting response, EVOLTRA can for some patients facilitate access to an allograft.